CADx Medical Systems can now market its Second Look CAD product in the U.S., following FDA approval of the system. The subsidiary of Shire Pharmaceuticals Group is preparing to market the product to hospitals, clinics, and
CADx Medical Systems can now market its Second Look CAD product in the U.S., following FDA approval of the system. The subsidiary of Shire Pharmaceuticals Group is preparing to market the product to hospitals, clinics, and mammography centers across the U.S. The decision follows receipt by the company Nov. 21 of an approvable letter from the regulatory agency. Second Look is based on imaging algorithms used by the U.S. military to automatically recognize targets. Approved for both screening and diagnostic use, Second Look will be marketed to radiologists as a tool for highlighting the most critical masses and microcalcifications on mammograms. Clinical trials demonstrated that 26.2% of lesions otherwise missed could be detected with Second Look.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).